Abstract: The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery?. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.

Abstract: A cell preservation medium, a cell recovery medium and a cell culture medium, and methods which employ the media, are provided.

Abstract: The present disclosure provides a method of fabricating cell, such as stem cell, arrays on a carrier where the surface energy of the carrier has been modified and patterned so that only areas of low contact angle are wetted by a water based cell solution. The patterned cell solution when applied to the carrier surface then self assembles into a 3 dimensional micro pattern on the carrier that mimics the surface topography of mammalian organs.

Abstract: The present disclosure provides a method of performing a functional assay on human spheroids, e.g., three-dimensional human cell spheroids using, in one embodiment, a fluorometric imaging plate reader.

Abstract: The present subject matter discloses various exemplary projective capacitive micro structured electrode arrays for measuring the impedance and action potential of living cells in particular induced pluripotent stem cells that are subsequently differentiated into cardiomyocytes and neurons. In one exemplary system a projective capacitive electrode array with cardiomyocytes attached onto the electrodes is formed and electrical measurements of live cell responses when exposed to external stimulants, such as small molecule drugs or biologically active compounds is recorded.

Abstract: The present disclosure provides a method of performing a functional assay on human spheroids, e.g., three-dimensional human cell spheroids using, in one embodiment, a fluorometric imaging plate reader.

Abstract: The present disclosure provides a method of manufacturing and differentiating mammalian stem cells, and in one embodiment human induced pluripotent stem cells (iPSc), e.g., manufacturing neuron progenitors, e.g., derived from iPSC, on a large scale by the use of an automated hollow fiber reactor system. In one embodiment, human iPSc that can be differentiated into cardiomyocytes or neuron progenitors are provided. The method comprises seeding a hollow fiber reactor with stem cells such as iPSc, or differentiated iPSc, growing and expanding the seeded cells using appropriate growth factors and nutrients, and harvesting the cells after expansion from the hollow fiber reactor walls, e.g., with the use of an enzyme. The method can produce billions of cells per week from seeding the reactor with a minimum number of starting stem cells or neuron progenitor cells.

Abstract: The present disclosure provides a fabrication process that results in creating large arrays of living cells, such as stem cells, which are subsequently exposed to nanoliter quantities of compounds to test the efficacy on cellular metabolism.

Abstract: The present disclosure provides a fabrication process that results in creating large arrays of living cells, such as stem cells, which are subsequently exposed to nanoliter quantities of compounds to test the efficacy on cellular metabolism.